Merck last year agreed to invest C$100m over five years in research and development in Quebec, a province of Canada, and has provided nearly $7m to AmorChem, a Canada-based life sciences venture capital fund.
Merck, a US-based drugs company, will invest C$6.8m ($6.9m) in AmorChem, a Canada-based life sciences venture capital fund, just days after setting up its own corporate venturing unit.
Merck last year agreed to invest C$100m over five years in research and development in Quebec, a province of Canada.
The majority of the C$41.25m AmorChem fund will come from Investissement Quebec and FIER Partenaires (a Quebec government-sponsored fund) as well as C$8.25 in total from companies, such as Merck.
The…
